Paxman AB (publ) (PAX.ST)
SEK 64.4
(2.55%)
SEK 64.4
(2.55%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 210.11 Million SEK | 34.05% |
| 2022 | 156.74 Million SEK | 62.93% |
| 2021 | 96.2 Million SEK | 23.25% |
| 2020 | 78.05 Million SEK | -8.47% |
| 2019 | 85.27 Million SEK | 46.97% |
| 2018 | 58.02 Million SEK | 85.19% |
| 2017 | 31.33 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 63.41 Million SEK | 8.18% |
| 2024 Q1 | 58.62 Million SEK | 5.45% |
| 2023 Q3 | 61.23 Million SEK | 20.13% |
| 2023 FY | 210.11 Million SEK | 34.05% |
| 2023 Q1 | 42.32 Million SEK | -6.32% |
| 2023 Q2 | 50.97 Million SEK | 20.45% |
| 2023 Q4 | 55.58 Million SEK | -9.22% |
| 2022 Q1 | 27.94 Million SEK | -4.69% |
| 2022 Q4 | 45.17 Million SEK | 9.28% |
| 2022 Q3 | 41.33 Million SEK | 15.17% |
| 2022 Q2 | 35.89 Million SEK | 28.45% |
| 2022 FY | 156.74 Million SEK | 62.93% |
| 2021 Q1 | 20.85 Million SEK | 14.2% |
| 2021 Q2 | 22.75 Million SEK | 9.11% |
| 2021 Q3 | 23.26 Million SEK | 2.25% |
| 2021 Q4 | 29.31 Million SEK | 26.0% |
| 2021 FY | 96.2 Million SEK | 23.25% |
| 2020 Q1 | 24.3 Million SEK | 6.58% |
| 2020 Q3 | 17.69 Million SEK | -0.52% |
| 2020 Q4 | 18.26 Million SEK | 3.22% |
| 2020 FY | 78.05 Million SEK | -8.47% |
| 2020 Q2 | 17.78 Million SEK | -26.83% |
| 2019 Q4 | 22.8 Million SEK | -0.63% |
| 2019 FY | 85.27 Million SEK | 46.97% |
| 2019 Q1 | 17.79 Million SEK | -3.53% |
| 2019 Q2 | 21.72 Million SEK | 22.09% |
| 2019 Q3 | 22.95 Million SEK | 5.66% |
| 2018 Q3 | 16 Million SEK | 27.02% |
| 2018 Q4 | 18.44 Million SEK | 15.25% |
| 2018 Q2 | 12.6 Million SEK | 14.82% |
| 2018 FY | 58.02 Million SEK | 85.19% |
| 2018 Q1 | 10.97 Million SEK | 21.3% |
| 2017 FY | 31.33 Million SEK | 0.0% |
| 2017 Q1 | 6.86 Million SEK | 0.0% |
| 2017 Q2 | 7.13 Million SEK | 3.9% |
| 2017 Q3 | 8.29 Million SEK | 16.27% |
| 2017 Q4 | 9.04 Million SEK | 9.12% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -3266.72% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 84.697% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 84.697% |
| Arcoma AB | 163.01 Million SEK | -28.894% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -3.004% |
| BICO Group AB (publ) | 2.23 Billion SEK | 90.618% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 63.223% |
| CellaVision AB (publ) | 677.29 Million SEK | 68.977% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -2439.792% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -21422.185% |
| C-Rad AB (publ) | 424.61 Million SEK | 50.516% |
| Duearity AB (publ) | 1.65 Million SEK | -12603.567% |
| Dignitana AB (publ) | 86.06 Million SEK | -144.143% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -1939.971% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.34% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -2868.472% |
| Integrum AB (publ) | 104.11 Million SEK | -101.805% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -24483.742% |
| Mentice AB (publ) | 273.61 Million SEK | 23.206% |
| OssDsign AB (publ) | 112.15 Million SEK | -87.342% |
| Promimic AB (publ) | 37.07 Million SEK | -466.811% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -86013.525% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -803.923% |
| ScandiDos AB (publ) | 60.42 Million SEK | -247.709% |
| Sectra AB (publ) | 2.96 Billion SEK | 92.91% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -36.558% |
| Senzime AB (publ) | 35.75 Million SEK | -487.674% |
| SpectraCure AB (publ) | 318 Thousand SEK | -65974.528% |
| Stille AB | 294.89 Million SEK | 28.748% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 94.017% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 64.836% |